Skip to content
PICO Portalanswers from OpenAlex

Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy

PaperCitations, authors & open-access status

Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy is a paper indexed in PICO Portal from OpenAlex.

How many citations does Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy have?

PICO Portalcitation count

Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy has 25 citations in the OpenAlex counts PICO Portal stores.

When was Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy published?

PICO Portalyear

Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy has 2024 year in the PICO Portal index.

What is the open-access status of Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy?

PICO Portaloa status

Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy has gold oa status in the PICO Portal index.

What is the DOI of Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy?

PICO Portaldoi

The DOI for Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy is on the source record.

What is the PMID of Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy?

PICO Portalpmid

The PMID for Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy is on the source record.

What is the OpenAlex record for Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy?

PICO Portalopenalex

The OpenAlex for Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial